BSH 2023 | The value of FLT3 inhibitors in AML and focus for future trial designs
In this video, Steven Knapper, MRCP, FRCPath, DM, Cardiff University, Cardiff, UK, discusses the value of FLT3 inhibition as a novel therapeutic strategy for acute myeloid leukemia (AML). First generation FLT3 inhibitors such as midostaurin have been approved for treating newly diagnosed AML, whilst second generation FLT3 inhibitors such as gilteritinib are used in the relapsed/refractory (R/R) setting. Prof. Knapper also comments on the importance of conducting future studies to compare these first and second generation FLT3 inhibitors and to explore the possibility of combining these with other promising regimens such as azacitidine and venetoclax. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Abbvie: advisory board
Astellas: advisory board, speakers’ bureau
Jazz: advisory board membership, speakers’ bureau
Novartis: research funding, speakers’ bureau
Pfizer: advisory board, speakers’ bureau
Servier: advisory board, support for conference attendance
